Drug Trial Radar · NCT02132988
Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: May 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
110
Planned (sponsor's estimate)
Start
Nov 2013
Primary completion
Nov 2017
Study completion Nov 2018
Sponsor
- Lead sponsor
- Mackay Memorial HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- OBI Pharma, Inc
- First posted
- May 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after cytoreductive surgery and platinum-based chemotherapy as initial treatment for primary disease or as salvage treatment for first relapse.
Conditions
- Ovarian Cancer
Interventions
OPT-822/OPT-821Biological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Until disease progression or up to 5 years after the enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mackay Memorial Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.